Geneva, March 31 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120890) titled 'The Efficacy and Safety of Tirofiban for Acute Branch Atherosclerosis disease: a prospective, randomised, open-label, blinded-end point, multi-centre trial' on March 22.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Chengdu Second People's Hospital
Condition:
Acute branch Atheromatous Disease(BAD)
Intervention:
Trial Group:Tirofiban hydrochloride sodium chloride injection: bolus dose of 0.4 ug/kg/min for 30 min, followed by maintenance infusion at 0.1 ug/kg/min for 48 hours
dual antiplatelet therapy with aspirin 100 mg/d and clopidogrel 75 mg/d (loading dose of 300 mg) initiated...